Pharvaris N.V.
- PHVS
- NASDAQ
- Biotechnology
- Rare Disease (Angioedema)
- Bradykinin Antagonist
- Clinical-Stage Biopharma
$29.17
Today +5.16%Quote Oct 19, 2026, 04:59 PM UTC
−27.00%over the last month
Max drawdown −27.0%From 1-month high −27.0%3 months −17.3%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Pharvaris
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
148
Founded
2015
Market value
$2.04B
Quote Oct 19
Floor
$29.02
0.5% below price
Resistance
$29.93
2.6% above price
Price vs analyst targets
14 analysts
Lowest target
$44.00Highest target
$75.00
$44.00Highest target
$75.00
- Price $29.17
- Average target $60.73
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 108% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about PHVSPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free